Announcements for medical specialists 03 May 2017 Announcements PRAC considers risk of severe allergic reactions with ambroxol- and bromhexine-containing medicines to be small. Update of product information is recommended European Medicines Agency concludes class review of bisphosphonates and atypical fractures Benefit-risk review of Multaq started Important safety information regarding Gadolinium - containing contrast agents and risk of Nephrogenic Systemic Fibrosis (only available in Bulgarian) European Medicines Agency recommends use of fibrates as second-line treatment Prev
